Identification of a novel CBFB-MYH11 fusion transcript in a patient with AML and inversion of chromosome 16
TO THE EDITOR The inversion 16 cytogenetic abnormality is frequently, but not exclusively, seen in the FAB (French-American-British) M4Eo subtype of acute myeloid leukemia (AML).
1 At the molecular level, it is associated with a CBFB-MYH11 fusion gene, but heterogeneity in the position of the CBFB and MYH11 breakpoints results in considerable variability in the fusion transcripts which are expressed, and which can be detected by RT-PCR (reverse transcriptase polymerase chain reaction) assays.
We wish to report a novel CBFB-MYH11 fusion transcript, detected in a patient with AML (FAB subtype M1). The patient (DA), a 68-year-old male, presented with cellulitis of the right foot. His hemoglobin was 97 g/l, white cell count 12.6 × 10 9 /l (71% blasts, 2% neutrophils), platelets 435 × 10 9 /l, and the marrow contained 83% blasts. There was no history of antecedent hematological disorder or malignancy, and there was no prior exposure to cytotoxic chemotherapy or ionising radiation. Cytogenetic analysis revealed the presence of cells with inversion of chromosome 16, and a subclone which also exhibited an isochromosome of 17q, ie 46,XY,inv(16)(p13q22) [6] /46,idem,i(17)(q10) [9] /46,XY [5] . He was treated with a single course of cytosine arabinoside (7 days) and daunorubicin (3 days) and achieved a complete cytogenetic response, but remained cytopenic with an excess of marrow blasts, suggesting that the AML may have evolved from a pre-existing myelodysplastic syndrome. Further chemotherapy was withheld because of coincident medical problems, and frank relapse occurred 9 months after the initial treatment.
Seminested RT-PCR for the detection of a CBFB-MYH11 fusion transcript was performed with Primer 1 and Primer 2 M 2 in the first round, and Primer 1 and Primer 5 M 3 in the second round. These primers generate a 418 bp first round PCR product and a 249 bp second round product for the most common fusion transcript (referred to as type A in a review 4 ). Amplification of cDNA from patient DA repeatedly generated a first round PCR product approximately 1 kb in size, and an appropriately smaller second round product (primer 5 M anneals 169 bp 5Ј to primer 2 M on MYH11) (Figure 1a ). This PCR product was not consistent with the expected sizes for the most common fusion transcripts. 4 Direct sequencing revealed an 864 bp second round product derived from a previously unreported CBFB-MYH11 fusion transcript with CBFB fused at nucleotide (nt) 495 to nt 1306 of MYH11 (Figure 1b and c).
Only one species of transcript was observed, whereas rearrangements associated with splice variants of PML-RAR␣ 5 and BCR-ABL 6 typically give rise to more than one species of PCR product. This suggests that the novel fusion transcript we detected is not the result of a splice variant of larger fusion transcripts such as types D or E, 4 although this possibility cannot be completely excluded. The rearrangement is in-frame with respect to both CBFB and MYH11, and nt 1306 has been identified as a putative intron-exon boundary within MYH11. 7 Both the CBFB and MYH11 portions of this rearrangement concur with published sequence data, with the exception of nt 1309 in MYH11. In our sequence this is a cytosine rather than the published thymine. 8 Using our patient's sequence to search GenBank we identified an unpublished sequence for the human smooth muscle myosin heavy chain gene with cytosine at nt 1309 (GenBank Accession Number X69292, submitted by K Okajima). This alternative sequence does not alter the leucine amino acid encoded at this position, and therefore may represent a polymorphism, although a PCR artefact has not been excluded, and heritability of cytosine at nt 1309 has not yet been demonstrated.
Prior exposure to DNA-topoisomerase II inhibitors has been identified as a risk factor for therapy-related AML (t-AML) associated with balanced translocations involving chromosome band 11q23, band 21q22, inv(16), t(15;17) and t(9;22). 9 In addition, it has been suggested that the less common forms of CBFB-MYH11 fusions are disproportionately represented in t-AML, particularly those following treatment with DNA-topoisomerase II inhibitors. 10 However, prior therapy with cytotoxic agents of any type was not a factor in our patient.
Identification of this novel transcript further emphasises the heterogeneity of breakpoints in the CBFB-MYH11 rearrangement and it will be interesting to determine if there is any prognostic significance associated with this and other types of CBFB-MYH11 fusion transcript. Although our patient failed to achieve complete remission, other factors such as age, concurrent medical problems, suboptimal chemotherapy and possible pre-existing myelodysplasia preclude drawing any conclusions about the impact of the unusual breakpoint on his response to treatment. 
NSW, Australia
Histologic diagnosis and precocious treatment in a case of isolated promyelocytic sarcoma TO THE EDITOR Granulocytic sarcoma (GS) is a rare extramedullary aggregate of malignant myeloid progenitor cells. Most cases of GS occur as a precursor to blast crisis in myeloproliferative and myelodysplastic syndromes or during the course of active acute myelogenous leukemia. 1 Less commonly GS represents the presenting feature of a still undiagnosed myelogenous leukemia and on rare occasions, it develops in healthy subjects, without concomitant blood or marrow evidence of hematologic disease. 2 GS is associated with every FAB leukemia subclass but it seldom arises in the course of an acute promyelocytic leukemia (APL: M3).
We recently observed a patient affected with multiple promyelocytic sarcomas in the absence of blood and marrow evidence of leukemia. He was referred to our institution complaining of mild fever (37.5-38°C) and severe chest pain. Physical examination revealed shortness of breath, pleural rubbing and the presence of two green, painless and slowly growing masses in the fronto-parietal scalp and in the lumbar region, respectively. No lymph node was palpable. A thorax and abdomen computed tomography revealed pleural thickening involving the posterior region of the 8th left rib with lytic lesions of the bone; a skull X-ray evidenced a 4 × 3 cm subcutaneous mass overlying the midline portion of the frontal bone without neural extension. An open incisional biopsy of the subcutaneous lumbar lesion revealed a green gelatinous mass histologically consistent with promyelocytic sarcoma. Immunohistochemical analysis confirmed the poorly differentiated myeloid nature of sarcoma cells with chloroacetate esterase, myeloperoxidase and CD43 being positive and with CD15 and UCHL1 negative. Full blood count was normal;
